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Thesis 
Cryopreservation of ovarian cortical tissue is an innovative method for the preservation of 
primordial follicles for the purpose of restoring fertility. This technique was developed for young female 
cancer patients enduring chemotherapy. However, there is a limited source of donors, which confines the 
research on follicular growth after grafting. Research shows that young female-to-male transsexuals, 
having been on androgen therapy for prolonged periods of time, can be potential donors. This paper 
explores transsexuality and the options available for making the transition to the opposite gender.  Then it 
will examine the process and effects of patients on androgen therapy and the effects it may or may not 
have on the primordial follicle pool. Finally, a thorough examination will look at the possibility of using 
ovaries from those undergoing sex-reversal operations as a source of tissue for research and possible 
oocyte donation in the future.  
What is transsexuality? 
 Transsexualism is viewed as an extreme form of gender dysphoria, where individuals feel that 
they belong to the gender opposite to their own gender. A distinction should be made between gender, 
which is formed by society, and sex, a person’s biological make up. Transsexualism was previously 
thought of as a mental disorder but the diagnosis was then removed from the Diagnostic and Statistical 
Manual of Mental Disorders and replaced by the term ‘gender identity disorder’ (Sutter, 2001). To reach 
the desired gender, transsexual people are treated by advanced hormonal and surgical therapy. Both 
possibilities take place after psychiatric evaluation, and surgery is only performed after the individual has 
successfully lived a specified amount of time in the desired gender role. The aim of cross-gender hormone 
therapy is an adjustment to the opposite sex via secondary sex characteristics. Specific hormones are 
administrated in decreasing doses in consecutive time intervals. When secondary sex characteristics have 
fully developed, the high-dose regime is switched to a lifelong low-dose procedure.  
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Endocrine Therapy  
Male to Female  
 An important component in treating transsexual people is cross-sex endocrine regimes. 
Feminizing endocrine treatment regimes of male to female transsexual people include various forms of 
estrogen, progestin and/or antiandrogens. Estrogen is crucial for feminizing MF people. The typical 
dosage is two to three times higher than that of hormone replacement therapy in postmenopausal women. 
Antiandrogens are used to lower serum levels of testosterone or completely block its binding to the 
androgen receptor. This decreases masculine secondary sexual characteristics. Progesterone boost breast 
growth and decrease irritability and breast sensitivity. The risk of combining estrogen and progesterone 
includes increase risk of coronary heart disease, stroke and pulmonary embolism. Some studies report a 
decrease in hemoglobin in estrogen treated MF transsexuals. In some cases, depression is increased in 
comparison to the general population. The risk is correlated to the dose and is similar to the side 
effects/risk in contraceptives.  
Female to Male 
 Testosterone is the key hormone in FM masculinizing endocrine treatment. This hormone is 
used for the development of secondary sexual characteristics and is given via injections. Oral testosterone 
is only available outside of the United States and contains lower serum testosterone levels. Typical 
testosterone doses range from 150-400 mg per month (Moore, 2003). Menstruation may not be 
sufficiently suppressed without the addition of progestin. GH-releasing hormone agonists are used in 
adolescent transsexual people to suspend puberty. This allows “cross-sex hormones to be postponed until 
adulthood” and creates “less psychological stress for the individual” (Moore, 2003). Menstruation is 
usually eliminated within several months. When evaluating the risks associated with androgen 
administration, it is important to consider that there have been limited studies conducted due to the small 
population of test subjects. From all the studies done, there were no reports of mortality. For patients with 
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extremely high levels of testosterone, there have been cases of cerebral vascular accidents in addition to 
weight gain, “decreased insulin sensitivity, poor lipid profile and an increase in hematocrit” raising 
concerns for cardiac issues (Moore, 2003). Testosterone treatment induces an increase of hemoglobin 
compared to the levels in biological men (Schlatterer, 2004). For both MF and FM transitions, 
“endocrinopathies and psychiatric problems are the most frequent disorders, followed by disease affecting 
the cardiovascular system, dermatological disorders, and chronic infectious diseases” (Schlatterer, 2004).  
Sex Reassignment Surgery 
 Hysterectomy and Oophorectomy 
 In addition to hormonal therapy, transsexuals seeking a complete transition to the opposite sex 
will have sex reassignment surgery (also known as genital reconstruction surgery, sex affirmation surgery 
or sex-change operation). There are three processes for FM transsexuals: hysterectomy, oophorectomy 
and metoidioplasty. Hysterectomy is the removal of the whole or part of the uterus and oophorectomy is 
the removal of the ovaries.  There are several types of hysterectomy: (1) partial or supracervical in which 
only the upper part of the uterus is removed and the cervix is left in place (2) total removal of the uterus 
and cervix (3) radical which removes the whole uterus, the tissue on both sides of the cervix and the upper 
part of the vagina. This last option is done when cancer present. After a hysterectomy, menstruation 
ceases and patients are unable to become pregnant. The surgery requires a 5 to 7 inch incision in the lower 
part of the stomach or a cut in the vagina through which the uterus is taken out. Laparoscopic 
hysterectomy is an advanced version in which a thin, lighted tube and small camera is inserted into the 
belly’s incision. The uterus is cut into smaller pieces and removed through the incision. Risks of having a 
hysterectomy include damage to close by organs (bowel, urinary tract, bladder, rectum, or blood vessels), 
pain during sexual intercourse, premature menopause (if the ovaries are removed) and anesthesia 
problems (breathing or heart problems).  
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Metoidioplasty  
Metoidioplasty requires testosterone treatment to stimulate clitoris growth. After substantial 
augmentation of the clitoris, a surgical procedure constructs the new penis. Surgeons form an undersized 
phallus from the elongated clitoris by “cutting the ligament that holds the clitoris in place under the pubic 
bone as well as cutting away some of the surrounding tissue” (Perovic, 2003). The surgery may also 
involve scrotoplasty, which is the creation of a scrotum by “insertion of testicular implants inside the 
labia majora and then joining the two labia to create the scrotal sac” (Perovic, 2003). The procedure 
involves pain and discomfort, requires a significant amount of time for recovery and may leave large 
sections of visible scarring. Due to the temperament of the skin grafts, there is always a risk of tissue 
death. Potential complications include the extrusion of testicular or penile implants, the formation of a 
stricture (an abnormal narrowing; blockage) or fistula (an abnormal connection; leakage) in the urethral 
passage. In some cases there is damage to the nerves resulting in numbness or loss of function (Perovic, 
2003).  
Effects on Reproduction 
All hormonal and surgical treatment options permanently remove the ability to reproduce in 
transsexual people. More and more people are diagnosed with transsexuality early in their life when they 
do not want children. Recently developed reproductive techniques make it possible for germ cells to be 
preserved for future use. In theory, transsexual people can use these germ cells after their transition. For 
male to female transsexual patients, sperm preservation occurs by freezing a substantial amount of sperm 
samples before starting hormone therapy. Feminizing hormonal therapy will induce hypspermatogensis in 
transsexual women that leads to azoospermia. Irrevocable sterility will occur after a lengthened period of 
hormone therapy and the addition of gender reassignment surgery (the removal of the testes). For 
transsexual men (female to male transsexual patient), masculinizing hormonal therapy leads to 
irreversible amenorrhea. Ovarian follicles will remain in place unless castration occurs, at which point 
there will be irreparable ovarian failure. To allow for future procreation, oocyte and embryo banking are 
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viable options. Oocyte banking entails hormonal stimulation, oocyte retrieval and subsequent freezing of 
the oocytes. Studies have shown that developed oocytes are very vulnerable to chromosomal damage 
throughout the freezing and thawing process. Embryo banking requires hormonal stimulation, oocyte 
retrieval, spermatozoa from a male donor and subsequent freezing of the embryos. 
Cortical Ovarian Tissue 
New treatments increase the success rate of healing many young patients with cancer. But the 
aggressive treatments come with the cost of losing ovarian function and fertility. With the improved rate 
for long-term survival of young women with malignancies undergoing chemotherapy, the preservation of 
future fertility is pulling in great interest. Chemotherapy uses antimetabolites, specifically the 
administration of doxyruicine, mitoxantrone or platinum that induces ovarian failure. High-dose 
chemotherapy and total body irradiation induces menopause in about 92% of all patients (Fabbri, 2006). 
Cryopreservation of ovarian cortical tissue allows for the preservation of primordial follicles, which can 
be used to restore fertility in young female cancer patients after chemotherapy.  Young patients have the 
option of preserving their ovarian tissue before chemotherapy but there are several important points to 
address before preservation is done. A patient’s age is an influential factor since ovarian tissues gathered 
after 38 years of age have a lower follicular population. Loss of early follicles is strictly related to 
patient’s age and follicular depletion is accelerated around 37 to 38 years (Fabbri, 2006). It is also known 
that “follicles are not homogeneously distributed within the ovarian cortex” (Fabbri, 2006). Therefore, it 
is recommended that a full ovary be removed. The quantity of tissue to cryopreserve is related to how 
chemotherapy influences the ovarian function. To reach optimal results, “healthy fresh ovarian tissue 
should be collected before anticancer treatment” (Fabbri, 2006). Therefore, young FM transsexual 
patient are excellent potential voluntary donors of ovarian cortical tissue. Studies show that follicular 
growth can be obtained in ovarian cortical grafts from transsexual donors who have been on androgen 
therapy because primordial follicles can recommence early growth after the hormonal treatment period.  
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Cryopreservation and Grafting  
To obtain ovarian tissue, the ovaries are bisected immediately after removal during reassignment 
surgery. “The medulla is removed and the cortex is scraped until all the medullary fragments are removed 
and only a 1 mm thick cortical slice remains. Fragments of the ovarian cortex are preserved in phosphate-
buffered formaldehyde” (Soleimani, 2006). Grafting is done by making an incision in the dorsal region 
and dissecting the skin free from the underlying muscles. The thawed ovarian cortical grafts are inserted 
deep in the subcutaneous space. To recover the graft, the dorsal skin is re-opened; the grafts are 
“dissected from the surrounding tissues and immediately placed in phosphate-buffered formaldehyde” 
(Soleimani, 2006).  
Source of primordial follicles  
Studies have shown in individuals who have received androgens, there was no “increased 
activation or depletion of primordial follicles” (Soleimani, 2006).  The patients’ ovaries contained similar 
amounts of primordial and primary follicles and women who have not received androgens. In all 
experiments conducted, results showed that there are no negative effects on the capability of ovarian 
follicles to resume growth from patients undergoing androgen therapy. All conclusive results support 
FM transsexuals as a source of follicles for experimental use and donor oocytes in the future (Broecke, 
2001). 
Rising Issues  
While the ability to locate a new resource of donations for research provides tremendous amounts of 
benefits for young female cancer survivors and the science community, there are oppositions regarding 
the source of the donation. There is a debate regarding the rights of ‘trannies’ to be legally recognized for 
their gender orientation and ‘moral conflicts’ of sex reassignment surgery. To some, the ability to change 
the nature of human beings with regards to the primary sexual organs is viewed as playing the power of 
God. We are fundamentally different because of our biological sex mechanisms and these features make 
us distinctly human. Many activists against transsexuals wonder where humanity will go if reassignment 
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surgery becomes the new phenomenon. These groups argue that the use of transsexual people’s tissues for 
donation will only promote the growth of the transsexual community and provide an ‘incentive’ for 
changing what humans were destined to have. On a scientific standpoint, some opponents argue that 
increasing numbers of transsexuals will create an unbalance population because of reproduction 
limitations.  
On the other hand, human rights activist groups are fighting for equal rights given to people of all nature, 
disregarding their sexual orientation or self-identification. Several scientists and surgeons from the studies 
used in this paper point out the greater strides made in follicular tissue research due to the new source of 
donors. All studies point out that recipients of the donations were informed about their donors and gave 
their consent before any further steps were taken. In this regard, some people argue that if there is 
agreement and safety in the procedure, there should not be an issue with transsexuals being a donor of 
primordial follicles.  
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